Company Concept
- Preoperative simulation reduces intraoperative trial and error -
Based on the CEO's experience in cardiovascular interventional therapy,
We aim to standardize cardiovascular treatment through AI navigation.
story
-Innovating endovascular treatment using VR and AI-
Our CEO has been involved in cardiovascular catheter treatment, mainly percutaneous coronary intervention (PCI),
I have felt that many intraoperative problems and the excessive use of auxiliary devices are caused by a failure to adequately analyze and integrate preoperative information .
Trial and error due to lack of intraoperative information places a heavy burden on patients and increases medical costs.
A prime example of this was the selection of a guiding catheter for PCI.
"Can we use CT data to find the right catheter for each patient?"
With this question as our starting point, we began our challenge.
First, we tried to reproduce the shape using 3D CAD, but we realized the limitations of this method as it was unable to reproduce the movements of actual clinical practice.
However, the next challenge, a guiding catheter simulation using Virtual Reality (VR), produced great results.(*1)
This is an approach that could only be achieved by a doctor with experience in PCI.
Furthermore, the barrier to introducing VR, which is the need to convert CT images into polygons, has been overcome with the AI-based automatic extraction app "SWORD AORTA."
This technology is being used in a wide range of treatment areas, including post-TAVI PCI and EVAR.
It has now evolved into "GUIDEYE Research & Education," which is equipped with AI-based VR simulation functions.
Our company was established in May 2023 with the aim of utilizing preoperative images to reduce trial and error in treatment.
We will continue our development with the aim of a future where endovascular treatment is performed using AI navigation.
Yoshinaga M, Muramatsu T, Higami H, Nasu K. Pre-Procedural Virtual Reality Guiding Catheter Simulation Navigating Successful Percutaneous Coronary Intervention of a Chronic Total Occlusion of an Anomalous Origin of the Right Coronary Artery. Catheter Cardiovasc Interv. 2025 Jan;105(1):124-130. doi: 10.1002/ccd.31296. Epub 2024 Nov 18. PMID: 39558482.
Member Introduction
CEO
Hirooki Higami
Cardiologist, Japanese Society of Cardiovascular Intervention and Therapeutics, Cardiologist, Japanese Circulation Society, Cardiologist, Japanese Society of Internal Medicine, General Medicine Specialist, Aortic Stent Graft, Chest and Abdominal Specialist, Kyoto University, Doctor of Medicine
He has extensive experience in cardiovascular treatment and has published numerous papers and presented at conferences.
He currently works as a cardiovascular catheterization surgeon at Gifu Heart Center and Teikyo University Hospital.
The hospital receives cases that are difficult to treat at other hospitals, and is able to collect a wide variety of data suitable for incorporating into AI. In addition, the provision of medical image information requires the consent of each patient under the approval of the ethical committee.
He also has an extensive network of experts in cardiovascular treatment.
CTO
Kazuhiko Matsumoto
Master's degree in Information Mechanical Engineering from the University of Tokyo
Founder of Ziosoft Inc.
With extensive experience in developing medical image-related applications, he founded ZioSoft Co., Ltd.
The company launched the ZioStation X-ray diagnostic device on the market.
He has now left ZioSoft and is working for our company and his own company, MedalVision.
He has advanced skills in creating applications for DICOM images and machine learning using AI.
Advisory board
Gaku Nakazawa
Professor, Department of Cardiology, Kinki University School of Medicine
Advisory board
Dai
Yamanouchi
Professor, Department of Vascular Surgery, Fujita Health University
Advisory board
Hiroaki Matsuda
Nagoya Heart Center, Department of Cardiology
Company Profile
社名
Anreal Twin 株式会社
所在地
東京都中央区銀座1-12-4 N&E BLD.7階
資本金
38,000,000円
設立
2023年5月2日
事業内容